Both studies demonstrated that statistically significant proportions of patients in the treatment groups achieved at least two-point improvements and clear or almost clear skin as measured by a scale called IGA.
The results will be submitted for presentation at future medical conferences and for publication.
The company says these two trials are part of five studies that will support global marketing applications. Additional data should be available later this year.
Baricitinib, a JAK enzyme inhibitor, was approved in the U.S. for rheumatoid arthritis in June 2018. It is marketed under the brand name Olumiant.
Now read: Karyopharm: Ready For Liftoff? »
Subscribe for full text news in your inbox